Esperion Therapeutics (NASDAQ: ESPR) reported Q1 EPS of ($0.79), $0.12 worse than the analyst estimate of ($0.67). Revenue for the quarter came in at $24.3 million versus the consensus estimate of $21.86 million.

For earnings history and earnings-related data on Esperion Therapeutics (ESPR) click here.